A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists

• Published in: Journal of the European Academy of Dermatology and Venereology Vol. 27; no. 1; pp. e131 - e135
• Main Authors: Petrof, G., Almaani, N., Archer, C.B., Griffiths, W.A.D., Smith, C.H.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.01.2013
• Subjects: Adalimumab; Adult; Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Dose-Response Relationship, Drug; Drug Administration Schedule; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G - therapeutic use; Infliximab; Male; Middle Aged; Pityriasis Rubra Pilaris - drug therapy; Pityriasis Rubra Pilaris - pathology; Receptors, Tumor Necrosis Factor - therapeutic use; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - therapeutic use; Young Adult
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/j.1468-3083.2012.04456.x

Background  Adult pityriasis rubra pilaris (PRP) type 1 is a rare chronic papulosquamous disorder with clinical and histological parallels with psoriasis. Treatment is challenging and recent case reports suggest a potential role for tumour necrosis factor (TNF) antagonists. Objectives  Our objective was to systematically review the literature for evidence of efficacy of TNF antagonists in the treatment of adult PRP. Methods  We performed a systematic search of the Cochrane library, EMBASE, Pubmed and MEDLINE databases. We defined diagnosis of PRP, classified clinical response and whether this was clearly attributed to TNF‐antagonists. We also reviewed disease, treatment duration and follow up. Results  Sixteen articles were selected for detailed review. From these, 12 articles (13 cases) met our predefined criteria and were included in the systematic review. The authors identified two more cases from their personal archive. A total of 15 evaluable cases were included for analysis. Twelve showed complete response (CR) (80%) to TNF‐antagonists with a mean time to maximal response of 5 months. In 10 of the CR cases (83%) this was clearly attributable to TNF antagonist therapy. Conclusion  These data indicate that TNF‐antagonists may be of value in treating adult type 1 PRP refractory to other systemic agents but selective reporting bias, together with the lack of standard diagnostic criteria and established spontaneous resolution in PRP, prevent any firm recommendations on their place in management.